EU/3/03/162

Table of contents

About

On 2 October 2003, orphan designation (EU/3/03/162) was granted by the European Commission to Monoclonal Antibodies Therapeutics (MAT), France, for yttrium (90Y) antiferritin polyclonal antibodies for the treatment of Hodgkin lymphoma.

In January 2013, Monoclonal Antibodies Therapeutics (MAT) changed its name to Mablife.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Yttrium (90Y) antiferritin polyclonal antibodies
Disease / condition
Treatment of Hodgkin lymphoma
Date of decision
02/10/2003
Outcome
Positive
Orphan decision number
EU/3/03/162

Sponsor's contact details

Mablife
Genopole Campus 1
5 rue Henri Desbruères
91030 Evry Cedex
France
Tel. + 33 160 917 880
Fax + 33 160 917 899
E-mail: contact@mablife.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating